Stem cell derived topical serum for patients with vitiligo

Phase 1

• Conditions: Vitiligo.; Vitiligo

• Registration Number: IRCT20230324057772N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

18 Years and older
Diagnosis of Vitiligo - Generalized vitiligo involving both sides of the body in one or more areas of the body (limbs, trunk, etc.)
Be able to understand the requirements of the study and be able to sign an informed consent form
Agree to follow the terms of the study and follow-up
Lack of corticosteroid-based treatment

Exclusion Criteria

Pregnant females
Infection in donor site
Kubner's evidence in the past
Keloidal tendency
Patients with focal or segmental vitiligo are defined as vitiligo that affects only one area of the body on one side of the body
Patients with vitiligo that affects more than 30% of their body surface
Patients who self-reported HIV or hepatitis C
Patients self-reported having uncontrolled diabetes mellitus

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Evaluation of skin repigmentation through skin biometry. Timepoint: Before and after of inerventation and 3 months after study completion. Method of measurement: Skin Biometry by using MPA9 probe.